MORF vs. SNDX, ARVN, RDHL, BBIO, IONS, OGN, CYTK, APLS, MDGL, and ALPN
Should you be buying Morphic stock or one of its competitors? The main competitors of Morphic include Syndax Pharmaceuticals (SNDX), Arvinas (ARVN), RedHill Biopharma (RDHL), BridgeBio Pharma (BBIO), Ionis Pharmaceuticals (IONS), Organon & Co. (OGN), Cytokinetics (CYTK), Apellis Pharmaceuticals (APLS), Madrigal Pharmaceuticals (MDGL), and Alpine Immune Sciences (ALPN). These companies are all part of the "pharmaceutical preparations" industry.
Morphic (NASDAQ:MORF) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, community ranking, analyst recommendations and profitability.
Syndax Pharmaceuticals received 290 more outperform votes than Morphic when rated by MarketBeat users. Likewise, 64.79% of users gave Syndax Pharmaceuticals an outperform vote while only 59.54% of users gave Morphic an outperform vote.
Morphic currently has a consensus target price of $51.50, indicating a potential upside of 69.58%. Syndax Pharmaceuticals has a consensus target price of $34.42, indicating a potential upside of 78.60%. Given Syndax Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than Morphic.
94.3% of Morphic shares are owned by institutional investors. 25.6% of Morphic shares are owned by company insiders. Comparatively, 4.1% of Syndax Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Syndax Pharmaceuticals had 1 more articles in the media than Morphic. MarketBeat recorded 4 mentions for Syndax Pharmaceuticals and 3 mentions for Morphic. Syndax Pharmaceuticals' average media sentiment score of 1.47 beat Morphic's score of 0.62 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media.
Morphic has higher earnings, but lower revenue than Syndax Pharmaceuticals. Morphic is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Morphic has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500.
Morphic's return on equity of -22.93% beat Syndax Pharmaceuticals' return on equity.
Summary
Syndax Pharmaceuticals beats Morphic on 10 of the 17 factors compared between the two stocks.
Get Morphic News Delivered to You Automatically
Sign up to receive the latest news and ratings for MORF and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MORF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
